Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Cancer Institute (NCI)
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Stanford University
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
St. Jude Children's Research Hospital
Massachusetts General Hospital
University of California, San Francisco
Chinese PLA General Hospital
Mayo Clinic
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Washington
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Washington
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Augusta University
AvenCell Therapeutics, Inc.
Regeneron Pharmaceuticals
Washington University School of Medicine
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
University of California, Irvine
St. Jude Children's Research Hospital
University of California, San Francisco
Peking University People's Hospital
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of Washington